HER2 status-Positive Posts on Medivizor
Navigation Menu

HER2 status-Positive Posts on Medivizor

Searching for patients with early-stage HER2+ breast cancer to trial a new treatment regime

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This study will examine how safe and effective the medication atezolizumab (Tecentriq) is in combination with other anti-cancer medicines for treating early stage HER2+ breast cancer. The main outcome that will be measured is how many patients completely respond to treatment, with no trace of the cancer remaining. The details...

Read More

Searching for patients with HER2 positive breast cancer that has spread to trial a new treatment

Posted by on Feb 23, 2019 in Breast cancer | 0 comments

In a nutshell This trial aims to see if combining two medications, T-DM1 (Kadcycla) and palbociclib (Ibrance) is better than just using T-DM1 in treating HER2+ breast cancer that has spread. The main outcome that will be measured is survival without the cancer growing or spreading. The study is being conducted in Arizona, the United States.  The...

Read More

Adding pertuzumab to treatment in breast cancer

Posted by on Dec 4, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

Looking for patients with HER2-positive inoperable breast cancer to examine the efficacy and safety of antibody-drug conjugate SYD985

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...

Read More

The effect of delaying trastuzumab therapy

Posted by on Jun 6, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated the effect of delaying trastuzumab (Herceptin) therapy in patients with breast cancer. The study concluded that delays in receiving trastuzumab therapy of 6 months or more leads to decreased overall survival and relapse-free survival time. Some background Some breast cancers depend on the human epidermal...

Read More